Summary & Overview
HCPCS Level II J9265: Paclitaxel Injection, 30 mg
HCPCS Level II code J9265 denotes a 30 mg unit of paclitaxel for intravenous chemotherapy administration. Paclitaxel is a widely used cytotoxic agent for multiple cancer indications; standardized reporting of doses with HCPCS Level II codes supports claims processing, utilization tracking, and payment clarity at a national level. The code is relevant across outpatient infusion centers, hospital outpatient departments, and oncology clinics that bill for administered chemotherapeutic agents.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for paclitaxel dosing, common service settings, and the role of J9265 in billing workflows. The publication summarizes national benchmarks and payer coverage patterns where available, outlines coding relationships and frequently paired service lines, and highlights policy updates affecting drug coding and reimbursement for infused oncology therapies.
This resource is designed for revenue cycle professionals, oncology clinic administrators, and policy stakeholders seeking concise guidance on coding and billing considerations for paclitaxel administration using HCPCS Level II code J9265.
Billing Code Overview
HCPCS Level II code J9265 represents an injection of paclitaxel, 30 mg. This code is used to report administration of the chemotherapeutic agent paclitaxel in 30-milligram units.
-
Service type: Drug administration (intravenous chemotherapy)
-
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing systemic chemotherapy for a solid tumor such as metastatic breast or ovarian cancer. The oncology infusion nurse prepares and administers intravenous chemotherapy using J9265 for paclitaxel dosed per body surface area or weight. The clinical workflow includes: pre-infusion assessment (vitals, lab review including CBC and liver function tests), chemotherapy order verification by the oncologist and pharmacist, premedication administration (antihistamines, corticosteroid, H1/H2 blockers as indicated), preparation of a weight‑based or BSA‑based dose of paclitaxel in pharmacy under sterile conditions, infusion via peripheral IV or implanted port with appropriate infusion pump, monitoring during and after infusion for hypersensitivity reactions or neuropathy, and documentation of dose, lot number, infusion time, and patient tolerance. Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, or physician office infusion suites. Typical patient scenario: a patient with metastatic breast cancer receiving a 3‑weekly paclitaxel regimen where each 30 mg increment of J9265 is billed according to the total milligram dose administered and documented in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component |